Capricor
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Capricor sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).
Capricor: 9 sponsored US clinical trials, none currently recruiting.
Capricor sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 1 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Duchenne Muscular Dystrophy, with 2 trials.
Top-decile sponsor footprint
Capricor ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Indexed trials (enrollment closed)
9 total, page 1 of 1
A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
NCT05126758
Open-label Extension of the HOPE-2 Trial
NCT04428476
Intravenous Infusion of CAP-1002 in Patients With COVID-19
NCT04623671
Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE)
NCT06304064
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
NCT03406780
HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)
NCT02485938
Safety Study of Cenderitide in Chronic Stable Heart Failure With Moderate Renal Impairment
NCT02603614
Safety Study of Cenderitide in Stable Chronic Heart Failure
NCT02359227
Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration
NCT01458405
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 6 |
| Phase 3 | 1 |
How the Capricor early-phase archive is shaped
9 indexed studies, none listed as recruiting (0% open); 6 completed (67%).
Phase mix: 1 late (III/IV) vs 8 early (I/II) (early-phase heavy).
Top condition: Duchenne Muscular Dystrophy (2 trials), 8 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Capricor: archived-pipeline peers nationwide
Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Capricor sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 9 archived trials
- 4D Molecular Therapeutics · 9 trials · 44% recruiting
- 9 Meters Biopharma · 9 trials · 0% recruiting
- Aadi Bioscience · 9 trials · 33% recruiting
- Ablynx, a Sanofi company · 9 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Capricor page
9 registered trials is a research-attention snapshot, not an endorsement of Capricor or any single study.
- None of Capricor's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Duchenne Muscular Dystrophy is the condition Capricor studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Duchenne Muscular Dystrophy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Capricor pipeline card: 9 registered trials from official public datasets.Report a data error.